Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.
Authors
André, FO'Regan, R
Ozguroglu, M
Toi, M
Xu, B
Jerusalem, G
Masuda, N
Wilks, S
Arena, F
Isaacs, C
Yap, Y
Papai, Z
Lang, I
Armstrong, Anne C
Lerzo, G
White, M
Shen, K
Litton, J
Chen, D
Zhang, Y
Ali, S
Taran, T
Gianni, L
Affiliation
Department of Medical Oncology, INSERM Unit U981, Université Paris Sud, Institut Gustave Roussy, Villejuif, France.Issue Date
2014-05
Metadata
Show full item recordAbstract
Disease progression in patients with HER2-positive breast cancer receiving trastuzumab might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab.Citation
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. 2014, 15 (6):580-91 Lancet OncolJournal
The Lancet OncologyDOI
10.1016/S1470-2045(14)70138-XPubMed ID
24742739Type
ArticleLanguage
enISSN
1474-5488ae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(14)70138-X